Category: In the News

A new initiative from School of Medicine and Health Sciences fourth-year graduate student Allison Graeter is focusing on addressing disparities in cancer treatment for persons living with HIV. Graeter started CancerFreeHIV in January to raise awareness about people with HIV’s higher risk of cancer and higher cancer mortality rates. CancerFreeHIV shares educational content on Twitter about cancer prevention and…

The Research to Accelerate Cures and Equity (RACE) for Children Act was approved by the U.S. Congress in 2017 and took effect on August 18, 2020. The act requires all new adult oncology therapeutics under consideration for approval by the U.S. Food and Drug Administration (FDA) to be evaluated for safety and efficacy in pediatric…

NEW ORLEANS ― Even within the first year of implementation, the Research to Accelerate Cures and Equity (RACE) for Children Act has made an impact. “In the year prior to RACE implementation, there were no approvals of therapeutics that required pediatric studies,” said Brittany Avin McKelvey, PhD, science policy analyst with Friends of Cancer Research…

The Research to Accelerate Cures and Equity Act led to an increase in required pediatric studies for recently approved cancer therapies within the first year of the act’s implementation, according to study results. Researchers presented the findings during American Association for Cancer Research Annual Meeting. Rationale and methods “Significant progress has been made in cancer…

NEW ORLEANS – In its first year of implementation, the RACE Act has resulted in increased requirements for more recently approved cancer drugs to be studied for potential use in pediatric patients, according to data presented at the AACR Annual Meeting 2022, held April 8-13. The Research to Accelerate Cures and Equity (RACE) for Children Act was approved…

SAN DIEGO, April 07, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the launch of an integrated genomic scar analysis for homologous recombination deficiency (HRD) in the…

Biomarker-driven cancer care relies on precision companion diagnostics co-developed with targeted therapies in clinical trials. A one-drug/one-test strategy has been the norm in such co-development. But as biomarker-defined subsets of patients get smaller and smaller, what happens to patients with rare diseases or conditions? A new white paper from the Friends of Cancer Research (FOCR)…

The Accelerated Approval Integrity Act of 2022 (H.R. 6963) aims to remove loopholes in the Food and Drug Administration‘s accelerated approval pathway. The bill, however, fails to adequately consider the whole picture, and may inadvertently remove medications that simply can’t complete confirmatory trials within the narrow timeframe allowed. “Patients deserve to know that the drugs they are taking…

Norman “Ned” Sharpless, the director of the National Cancer Institute who had a short stint leading the Food and Drug Administration, announced Monday that he is stepping down at the end of April, the latest in a string of departures and job changes by senior health and science officials in the Biden administration. Sharpless, 55, said in an…

Ned Sharpless, one of the last presidential appointees from the Trump administration to be held over by President Joe Biden’s White House, will step down as director of the National Cancer Institute at the end of the month, the NCI announced Monday. The announcement comes about two months after Biden announced plans to reignite the…